TP53 alteration frequencies in subgroups of AML and MDS
| . | Specific subgroup according to WHO 2017 . | Number of cases . | Cases without TP53 aberration [n] . | Cases with TP53 aberration [n] . | Frequency of TP53 aberration [%] . |
|---|---|---|---|---|---|
| AML | AML-MRC∗ | 152 | 87 | 65 | 43 |
| AML with t(9;11)(p21;q23); KMT2A::MLLT3 | 26 | 23 | 3 | 12 | |
| AML with inv(3)(q21q26); GATA2::MECOM | 32 | 29 | 3 | 9 | |
| Acute promyelocytic leukemia with PML::RARA | 50 | 46 | 4 | 8 | |
| Acute monoblastic and monocytic leukemia | 14 | 13 | 1 | 7 | |
| Therapy-related AML | 19 | 18 | 1 | 5 | |
| AML with maturation | 52 | 50 | 2 | 4 | |
| AML without maturation | 30 | 29 | 1 | 3 | |
| Acute myelomonocytic leukemia | 33 | 32 | 1 | 3 | |
| AML with mutated RUNX1 | 43 | 42 | 1 | 2 | |
| AML with mutated NPM1 | 160 | 158 | 2 | 1 | |
| AML with biallelic mutation of CEBPA | 47 | 47 | 0 | 0 | |
| AML with inv(16)(p13q22); CBFB::MYH11 | 47 | 47 | 0 | 0 | |
| AML with t(6;9)(p23;q34); DEK::NUP214 | 10 | 10 | 0 | 0 | |
| AML with minimal differentiation | 14 | 14 | 0 | 0 | |
| AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 | 43 | 43 | 0 | 0 | |
| Total in AML | 772 | 688 | 84 | 11 | |
| MDS | Therapy-related MDS | 22 | 16 | 6 | 27 |
| MDS with isolated del(5q) (MDS 5q–)∗ | 104 | 83 | 21 | 20 | |
| MDS-EB-2∗ | 151 | 126 | 25 | 17 | |
| MDS-EB-1∗ | 149 | 128 | 21 | 14 | |
| MDS-RS-SLD | 42 | 38 | 4 | 10 | |
| MDS-RS-MLD∗ | 148 | 136 | 12 | 8 | |
| MDS-SLD | 18 | 17 | 1 | 6 | |
| MDS-MLD | 113 | 107 | 6 | 5 | |
| Total in MDS | 747 | 651 | 96 | 13 | |
| In total cohort | 1519 | 1339 | 180 | 12 |
| . | Specific subgroup according to WHO 2017 . | Number of cases . | Cases without TP53 aberration [n] . | Cases with TP53 aberration [n] . | Frequency of TP53 aberration [%] . |
|---|---|---|---|---|---|
| AML | AML-MRC∗ | 152 | 87 | 65 | 43 |
| AML with t(9;11)(p21;q23); KMT2A::MLLT3 | 26 | 23 | 3 | 12 | |
| AML with inv(3)(q21q26); GATA2::MECOM | 32 | 29 | 3 | 9 | |
| Acute promyelocytic leukemia with PML::RARA | 50 | 46 | 4 | 8 | |
| Acute monoblastic and monocytic leukemia | 14 | 13 | 1 | 7 | |
| Therapy-related AML | 19 | 18 | 1 | 5 | |
| AML with maturation | 52 | 50 | 2 | 4 | |
| AML without maturation | 30 | 29 | 1 | 3 | |
| Acute myelomonocytic leukemia | 33 | 32 | 1 | 3 | |
| AML with mutated RUNX1 | 43 | 42 | 1 | 2 | |
| AML with mutated NPM1 | 160 | 158 | 2 | 1 | |
| AML with biallelic mutation of CEBPA | 47 | 47 | 0 | 0 | |
| AML with inv(16)(p13q22); CBFB::MYH11 | 47 | 47 | 0 | 0 | |
| AML with t(6;9)(p23;q34); DEK::NUP214 | 10 | 10 | 0 | 0 | |
| AML with minimal differentiation | 14 | 14 | 0 | 0 | |
| AML with t(8;21)(q22;q22); RUNX1::RUNX1T1 | 43 | 43 | 0 | 0 | |
| Total in AML | 772 | 688 | 84 | 11 | |
| MDS | Therapy-related MDS | 22 | 16 | 6 | 27 |
| MDS with isolated del(5q) (MDS 5q–)∗ | 104 | 83 | 21 | 20 | |
| MDS-EB-2∗ | 151 | 126 | 25 | 17 | |
| MDS-EB-1∗ | 149 | 128 | 21 | 14 | |
| MDS-RS-SLD | 42 | 38 | 4 | 10 | |
| MDS-RS-MLD∗ | 148 | 136 | 12 | 8 | |
| MDS-SLD | 18 | 17 | 1 | 6 | |
| MDS-MLD | 113 | 107 | 6 | 5 | |
| Total in MDS | 747 | 651 | 96 | 13 | |
| In total cohort | 1519 | 1339 | 180 | 12 |
AML and MDS subgroups are sorted according to frequency of TP53 alteration, respectively.
MDS-MLD, MDS with multilineage dysplasia; MDS-RS-MLD, MDS with multilineage dysplasia with ring sideroblasts; MDS-RS-SLD, MDS with single lineage dysplasia with ring sideroblasts; MDS-SLD, MDS with single lineage dysplasia.
The subgroups in which more than 10 cases had TP53 alterations are highlighted in gray. Those were thus selected for further detailed analysis of the alteration type and OS.